Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Trial details
- Registry ID
- NCT05130866
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as AR-42; NSC-D736012; OSU-HDAC42
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866 | RXRX | Phase 2, Phase 3 | Terminated | 2025-08-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |